Through our advocacy, we fight for you. We fight for your right to affordable medications and technology, your right to be treated fairly at work and school, your right to quality health care, and so much more.
Included in the Calendar Year 2026 Medicare Home Health Proposed Rule, the Centers for Medicare & Medicaid Services (CMS) proposed a change to their coverage policies for diabetes technology that may restrict access to critically important technologies like continuous glucose monitors (CGMs), insulin pumps, and automated insulin delivery (AID) systems for Medicare beneficiaries.
As you know, diabetes technologies such as these have transformed the diabetes management landscape by improving outcomes and making the condition easier to live and thrive with. Advancements in diabetes technology have better enabled people to effectively manage their condition.
The Standards of Care in Diabetes—2025 (Standards of Care) of the American Diabetes Association® (ADA) states that technology is rapidly changing, but there is no universal approach to technology use in people with diabetes. The type(s) and selection of devices should be individualized based on a person’s specific needs, circumstances, preferences, and skill level.
The ADA is concerned that the payment and coverage proposals related to CGMs and insulin pumps laid out in this rule—along with CMS’ intent to apply CGMs and insulin pumps to the next, or a future, round of competitive bidding—may unintentionally restrict access to these critically important technologies for Medicare beneficiaries with diabetes.
Please join us in our efforts to help oppose this regulatory change by submitting a public comment in opposition to the proposed CMS policy by 5:00 p.m. ET on Friday, August 29.
To assist you with this process, we have included the seventh chapter of the ADA's 2025 Standards of Care, Diabetes Technology, to use as a resource.
Sincerely,
Laura Friedman
Vice President, Regulatory Affairs
American Diabetes Association
Below is a sample letter. Please personalize your comment as much as possible so CMS understands your specific perspective.
August XX, 2025
Mehmet Oz, MD
Administrator
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, MD 21244
Attention: File Code: CMS–1828– P
Submitted via regulations.gov
Re: Medicare and Medicaid Programs; Calendar Year 2026 Home Health Prospective Payment System (HH PPS) Rate Update; Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program Updates
Dear Administrator Oz:
Introduce yourself, include who you represent, the patient population you serve, or any specifics about yourself or your practice that you would like to share.
Coverage of Diabetes Technology in Medicare
(I/organization) am/is writing to comment on the proposal by the Centers for Medicare & Medicaid Services (CMS) to include continuous glucose monitors (CGMs), insulin pumps, and automated insulin delivery (AID) systems in any future Medicare Durable Medical Equipment Prosthetics, Orthotics, and Supplies (DMEPOS) competitive bidding program.
Diabetes technologies, like CGMs, insulin pumps, and AID systems, have transformed the diabetes management landscape by improving outcomes and making the condition easier to live and thrive with. Advancements in diabetes technologies have better enabled people to effectively manage their condition. The American Diabetes Association® states that the type(s) and selection of devices should be individualized based on a person’s specific needs, circumstances, preferences, and skill level.1
To that end, (I/we/name of entity) (am/are) concerned that the proposals laid out in this rule may restrict Medicare beneficiaries’ access to these critically important technologies. This proposal lacks the recognition of the functional benefits of the full range of diabetes technologies, which reflect the reality that each individual with diabetes who uses one of these devices determines, with their health care provider, the proper device based on personal factors and the specific needs they must meet to manage their condition.
Share your story:
Other potential points for your letter:
Thank you for the opportunity to submit these comments. Should you have any questions or seek additional information, please reach out to (name/contact information).
1American Diabetes Association: Standards of Care in Diabetes 2025, Diabetes Care 48: Supp. 1 (January 2025), p. S146
Sincerely,
Name
Title (if applicable)
Use your voice to help people with diabetes thrive. Stand up for diabetes research and programs, health care, insulin affordability, and diabetes prevention, and help support people living with and impacted by diabetes everyday—until we find a cure.
The American Diabetes Association’s (ADA’s) Engagement Platform makes it easy to use your voice to help support the diabetes community on the issues that matter most. We’ve made it easy for you by creating a pre-written draft letter ready to send!
At the ADA, we stress the importance of sharing your story because your experience provides a face behind the very real challenges of diabetes. But have you ever wondered what the impact of diabetes is on your state or the national cost of diabetes? That’s where we come in.
The ADA has many resources to help you raise awareness of diabetes and supplement your requests when contacting your elected officials, including those on the following topics:
We developed a guide to help you share your story with your social networks, community, and elected officials. Join us and raise awareness of diabetes among your friends, family, and community.
The ADA’s Safe at School® campaign is committed to ensuring students with diabetes are safe, treated fairly, and have full access to all school-sponsored activities such as field trips and after-school clubs. Below are some recent updates, but you can explore more helpful resources on the Safe at School page.